Finding Hope with Metastic Melanoma: Michelle's Immunotherapy Story
Since being diagnosed with melanoma in 2010, Michelle Boyer has participated in six different immunotherapy clinical trials, which she credits with prolonging her life. #CIM15 #PatientStories
The trial she is on now, of the anti-PD-L1 drug atezolizumab (MPDL3280A) in combination with the targeted therapy cobimetinib, has caused her tumors to stop growing, and shrink in some cases. For Michelle and her family, participating in clinical research is about finding hope while seeking a cure. http://www.cancerresearch.org/patients
This video is presented as part of the Cancer Research Institute 3rd Annual Cancer Immunotherapy Month awareness campaign this June 2015. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. http://www.cancerresearch.org/june
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org
-
Category
No comments found